Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27542616 | 1.00 | KMT2A (0.65) | KMT2AMAPK1HSD17B2GRM5HSD11B1 | |
| SCHEMBL4716523 | 1.00 | KMT2A (0.65) | KMT2AMAPK1HSD17B2GRM5HSD11B1 | |
| SCHEMBL523453 | 0.91 | KMT2A (0.65) | KMT2AMAPK1HSD17B2GRM5HSD11B1 | |
| SCHEMBL14659304 | 0.91 | KMT2A (0.65) | KMT2AMAPK1HSD17B2GRM5HSD11B1 | |
| SCHEMBL523454 | 0.91 | KMT2A (0.65) | KMT2AMAPK1HSD17B2GRM5HSD11B1 | |
| SCHEMBL27886063 | 0.91 | KMT2A (0.65) | KMT2AMAPK1HSD17B2GRM5HSD11B1 | |
| SCHEMBL10195853 | 0.91 | KMT2A (0.65) | KMT2AMAPK1HSD17B2GRM5HSD11B1 | |
| SCHEMBL5618767 | 0.89 | KMT2A (0.53) | KMT2AMAPK1HSD17B2GRM5MAPT | |
| SCHEMBL5618768 | 0.89 | KMT2A (0.53) | KMT2AMAPK1HSD17B2GRM5MAPT | |
| SCHEMBL12414687 | 0.88 | KMT2A (0.64) | KMT2AMAPK1HSD17B2GRM5HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1262477-B1 | ANTI-ACID-FAST BACTERIAL AGENTS CONTAINING PYRIDONECARBOXYLIC ACIDS AS THE ACTIVE INGREDIENT | DAIICHI SANKYO CO LTD (JP) | 2008-09-03 | — | — | EP | disclosed |
| US-7186843-B2 | potent antibacterial activity against various bacteria including drug-resistant strains | DAIICHI PHARMACEUTICAL CO. LTD. (JP) | 2007-03-06 | — | — | US | disclosed |
| US-7176313-B2 | Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7176313-B2 | Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-6825353-B2 | AN AMINE SUBSTITUENT AT THE 7-POSITION OF THE QUINOLONE-CARBOXYLIC ACID DERIVATIVE IS PRODUCED; BACTERICIDES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-30 | — | — | US | disclosed |
| US-20040209940-A1 | Aminomethylpyrrolidine derivatives having aromatic substituents | DAIICHI PHARMACEUTICAL CO., LTD. | 2004-10-21 | — | — | US | disclosed |
| US-6762181-B1 | BROAD ANTIBACTERIAL ACTIVITY INCLUDING DRUG RESISTANT STAPHYLOCOCCUS AUREUS (MRSA), PNEUMOCOCCUS (PRSP) AND ENTEROCOCCUS (VRE); SAFELY USED IN CONJUCTION WITH NONSTEROIDAL ANTIINFLAMMATORY DRUGS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-07-13 | — | — | US | disclosed |
| EP-1182202-B1 | AMINOMETHYLPYRROLIDINE DERIVATIVES HAVING AROMATIC SUBSTITUENTS | DAIICHI SEIYAKU CO (JP) | 2004-06-02 | — | — | EP | disclosed |
| US-20030119848-A1 | Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-06-26 | — | — | US | disclosed |
| US-20030060631-A1 | Process for producing quinolonecarboxlic acids and intermediates thereof | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
| EP-1262477-A1 | ANTI-ACID-FAST BACTERIAL AGENTS CONTAINING PYRIDONECARBOXYLIC ACIDS AS THE ACTIVE INGREDIENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-12-04 | — | — | EP | disclosed |
| EP-1258478-A1 | PROCESS FOR PRODUCING QUINOLONECARBOXYLIC ACIDS AND INTERMEDIATES THEREOF | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-11-20 | — | — | EP | disclosed |
| EP-1182202-A1 | AMINOMETHYLPYRROLIDINE DERIVATIVES HAVING AROMATIC SUBSTITUENTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119848-A1 | Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient | PGD, PPA1, FASTKD1 | KMT2A 4178/4885MAPK1 365/4885HSD17B2 3641/4885 |
| US-20040209940-A1 | Aminomethylpyrrolidine derivatives having aromatic substituents | Q6ZSR9, NAT1, NAT10 | KMT2A 630/4885MAPK1 1910/4885HSD17B2 3196/4885 |
| US-20030060631-A1 | Process for producing quinolonecarboxlic acids and intermediates thereof | NQO2, QPCT, QARS1 | KMT2A 2429/4885MAPK1 2580/4885HSD17B2 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.